Y-C Shen

Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems

A. Cheng, C. Hsu, Y. Shao, 2012, British Journal of Cancer.

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

Chih-Hung Hsu, A. Cheng, Siyi Liu, 2012, British Journal of Cancer.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

Y. Yen, G. Bhattacharyya, S. Choo, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Abstract P3-14-18: Result of Phase I Part of a Phase I/II Study of Lapatinib (L) Plus Oral Vinorelbine (oVNR) in Metastatic Breast Cancer (MBC) Patients Overexpressing ErbB2

A. Cheng, C. Huang, Y-C Shen, 2010 .

Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract

K. Yeh, A. Cheng, C. Hsu, 2004, British Journal of Cancer.

Lack of efficacy of troglitazone at clinically achievable concentrations, with or without 9-cis retinoic acid or cytotoxic agents, for hepatocellular carcinoma cell lines

A. Cheng, C. Hsu, Y-C Shen, 2004, British Journal of Cancer.